Design and development of novel cyclosporine A lipid nanoparticle formulations appropriate for oral delivery

  1. Guada ., Melissa
Supervised by:
  1. María José Blanco Prieto Director
  2. María del Carmen Dios Vieitez Director

Defence university: Universidad de Navarra

Fecha de defensa: 16 February 2016

Committee:
  1. Ángel Concheiro Nine Chair
  2. Azucena Aldaz Pastor Secretary
  3. Ana Isabel Torres Suárez Committee member
  4. Julen Oyarzabal Santamarina Committee member
  5. Antonio José Leitâo das Neves Almeida Committee member

Type: Thesis

Teseo: 121639 DIALNET lock_openDadun editor

Abstract

Cyclosporine A (CsA) is a well-known immunosuppressive agent that gained considerable importance in transplant medicine in the late 1970s due to its selective and reversible inhibition of T-lymphocytes. While CsA has been widely used to prevent graft rejection in patients undergoing organ transplant it was also used to treat several systemic and local autoimmune disorders. Currently, the neuro- and cardio-protective effects of CsA (CiCloMulsion®; NeuroSTAT®) are being tested in phase II and III trials respectively and NeuroSTAT® received orphan drug status from US FDA and Europe in 2010. The reformulation strategies focused on developing Cremophor® EL free formulations and address variable bioavailability and toxicity issues of CsA. This review is an attempt to highlight the progress made so far and the room available for further improvements to realize the maximum benefits of CsA.